With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health system by requiring less inpatient care. Drugs that are more potent per gram could be priced competitively with lower-potency incumbents, increasing profits for the manufacturer and decreasing infusion times for the patient. Processes that are difficult to scale, such as cell therapy manufacturing, will become increasingly streamlined, allowing manufacturers to reduce prices while increasing profits.”
Read the full story.